MXPA96003241A - Pharmaceutical products to cure tumor diseases and procedure for its preparation - Google Patents

Abstract

The invention relates to a process for the pration of products for curing tumor diseases which include as an active agent water or aqueous solutions, are suitable for human consumption, have a deuterium content between 0.1 and 110 ppm, optionally together with carriers and / or auxiliary substances, and take the form of pharmaceutical products or medicinal solutions

Description

PHARMACEUTICAL PRODUCTS TO CURE TUMOR DISEASES AND PROCEDURE FOR PREPARATION FIELD OF THE INVENTION This invention relates to pharmaceutical products for curing tumor diseases and to a process for preparing said products. BACKGROUND OF THE INVENTION Currently there are several methods (surgical intervention, irradiation therapy, hormone therapy, application of human agents) to combat malignant tumors. All these methods, together with recent advances in diagnosis, have produced great advances in the last decade, but despite these results, the methods applied have many drawbacks. The main reason for the problem is that as the molecular mechanism of cell proliferation is not yet known, intervention during the course of the disease with the available means is quite difficult. Therefore, the way to cure the disease or at least to delay its development, frequently includes the elimination of some parts of organs or the appearance of problems in the blood formation process when anti-tumor agents are used, etc. The appropriate answer to this question can only be expected when you have complete knowledge of the - submolecular or molecular processes that play a key role in the initiation of the process of cell proliferation. Through the development of molecular biology, biological science is just before the time to know the decisive regulatory processes through which it will be possible to heal patients suffering from tumor diseases. Considering the recent results of molecular biology, it can be concluded that a prompt common response of eukaryotic cells to stimuli that activate proliferation is an increase in intracellular pH due to an exchange of extracellular Na + by intracellular H + through the plasma membrane [P. N. A. S. 79, 7778 to 7782 (1982)]. The conclusion that activation of the Na + / H + exchange system is essential to initiate cell growth has been confirmed by numerous experimental results. It has been found that a specific mutation that suppresses the Na + / H + exchange system prevents the growth of cells at a neutral pH and acid t (P.A. S. S. Ql, 4833 a 4837 (1984)]. Recent evidence indicates that growth factors activate the Na + / H + exchange system suggesting that said Na + / H + exchange system can function as a transmembrane signal transducer [Natura 304, 645 to 648 (1983)]. The relationship between the Na + / H + exchange system and the tumor character of cell families has also been proven. It has been found that the pH increases after transformation of a family of cells compared to a non-tumor parental family [P. N. A. S. 84, 2766 to 2770 (1978)]. A strong correlation has been found between the expression of the oncogene and the high intracellular pH, because the injection of Ha-ras code protein or of oncogenes of expression V-mos or H-ras in the cell, increases the intracellular pH by activating of the exchange system Na + / H + [Mol. Cell. Biol. 7, 1984 to 1988 (1987); Gene 54, 147 a 153 (1987)]. Similar changes have been discovered by activating another hydrogen ion transport system bound to the membrane. In this case, the ATPase gene was isolated from the yeast and used to transform families of mouse and monkey cells. The gene was expressed, and ATPase, through continuous proton expulsion, produced a sustained alkalinization of the cytoplasm. The really surprising result of this experiment was that the cells transformed by the yeast ATPase gene acquired cancerigenic properties [Nature 114, 438 to 440 (1988)]. This last experiment proves that the induction of cell proliferation is linked not only with the activation of the Na + / H + exchange system, but also, in general, with the activation of any other proton ejection system that can serve as a signal of cell proliferation. A simple explanation of the previous phenomenon may be that the proliferation of cells is initiated by the increase in intracellular pH. However, this explanation has not been confirmed by experiments, in which an artificial increase in cytoplasmic pH has not raised the activity of cell proliferation [J. Exp. Biol. 124. 359 to 373 (1986)]. The aforementioned molecular processes can be interpreted by investigating the possible role of hydrogen and deuterium in the control of said processes. In nature, the ratio of hydrogen to deuterium is around 6000: 1. Due to the 100% mass difference, the two isotopes show different behaviors in chemical reactions. The generally accepted point of view is that deuterium bonds that participate in chemical reactions decompose at a lower speed because of the isotope effect, so they require a higher activation energy [Symonyi Miklós and Fitos liona: Hydrogen Isotope Effect in Chemical Reactions (in Hungarian); (Recent Results in Chemistry) 46., 8 to 129 (1980)]. In enzymatic reactions, it can be measured in a similar way that - the reaction rate is 4 to 5 times higher with the hydrogen isotope, which has the lowest mass number [Biochem.

Pharmacol. 10, 3089-3094 (1981)]. In addition, the effects of deuterium on biological systems have been thoroughly investigated [Katz, J. J. and Crespi, H. L.: Isotope Effects in Biological Systems (eds.

Collins, C.J. and Bowman, N.S.) A.C. S. Monograph 167, van Nostrand Reinhold, New York, 1971, 286 to 363]. The common feature of these experiments is that the investigation of the effects of deuterium has generally been carried out by applying high concentrations of D20 (from 1 to 100%). It is widely accepted that deuterium has an activity that inhibits the reproduction and growth of bacteria, yeasts and plants. Mammals can tolerate D20 at a maximum concentration of 35%. A greater concentration produces in them lethal effects. In these experiments, deuterium was applied in concentrations between 100 and 10000 times the natural concentrations, which were ignored. A global review of hydrogen isotopes in precipitation has revealed that the deuterium content is in a field between 120 and 160 ppm, depending mainly on the place where the samples are taken. The differences between the hydrogen isotopes of - the plants, and therefore also the algae, can enrich the hydrogen [Schiegl,. E. and Vogel, J. C, Earth and Planet. Sci. Letters 7, 307-313 (1970); Ziegler, H. et al., Plant 128. 85 to 92 (1976)]. As a result of these processes, concentrations of deuterium, for example in creatures that eat plants, show alterations in a very narrow field, depending on the species and quantities of plants consumed. In the case of humans, the area in which the plants are grown is a decisive factor. According to the measurements, the deuterium content in tropical rain is 155 to 160 ppm, while this value is only 120 to 150 ppm in the temperate zones of the Earth. The difference is also visible in the deuterium content of the plants, with alterations between 10 and 20%. Although the mentioned phenomena have been observed, the experts have not given any importance to the deuterium content in the biological systems. SUMMARY OF THE INVENTION The basis of this invention is the recognition that the content of deuterium at a very low level (comprised between 120 and 160 ppm) in biological systems is essential to maintain the normal rate of cell proliferation and that the Deuterium deficiency increases the duration of cell cycles. That is, it has been proven that deuterium is a component of a submolecular regulatory system and that processes that temporarily raise the concentration of deuterium trigger the proliferation of cells. Another basis of the invention is the recognition that by consuming water or aqueous solutions containing deuterium in an amount lower than that contained in natural waters (for example juices diluted in water with deuterium decreased), the level of deuterium in the body Human can be diminished as a result of exchange processes and that in this way the proliferation of tumor cells can be stopped or the development of cancerous tumors can be prevented. Accordingly, the invention relates to products for curing tumor diseases, comprising water with a content of: deuterium comprised between 0.1 and 110 ppm, and / or aqueous solutions, suitable for human consumption, with a deuterium content as an agent active between 0.1 and 110 ppm, optionally with carriers and / or auxiliary substances. The products according to the invention are preferably pharmaceutical products of the physiological saline type or medicinal solutions, such as fruit syrups, soft drinks, or low alcohol or non-alcoholic beer, all having a deuterium content of between 0.1 and 110 ppm. In addition, the invention relates to a process - of preparing products for curing tumor diseases, comprising the operations of producing, by electrolysis and / or distillation, water and / or aqueous solutions with a deuterium content as an active agent comprised between 0.1 and 110 ppm, and transforming the water and / or the aqueous solution thus produced, optionally together with carriers and auxiliary substances, in pharmaceutical products or medicinal solutions. According to a preferred method of execution of the claimed process, saline physiological solutions are prepared as pharmaceutical products with a deuterium content of between 0.1 and 110 ppm. According to another preferred embodiment of the process of the invention, fruit syrups, soft drinks, or low alcohol or non-alcoholic beer are prepared as medicinal solutions with a deuterium content of between 0.1 and 110. ppm. The products of the invention are preferably formulated as injectable solutions, infusions, syrups, juices or moisturizing ointments with a deuterium content between 0.1 and 110 ppm. The products of the invention are suitable for curing tumor diseases. The basis of this therapeutic application lies in the fact that the application of solutions with deuterium decreased, with a content of deuterium between 0.1 and 110 ppm, also decreases the deuterium content of the organism. As a consequence of this process, the growth rate of cancer cells decreases, whereas healthy cells are>. still able to tolerate the decreasing concentration of deuterium. The ability of the method of the invention to treat tumor diseases has been tested by in vitro and in vivo assays carried out using water with decreased deuterium. The results of the test can be seen in figures 1 and 2, as well as in tables 1 to 4. DESCRIPTION OF THE DRAWINGS In figure 1, the growth of mouse fibroblast cells L929 is illustrated, after the synchronization in phase Gl in fluids nutrients prepared with water with a deuterium content decreased (v: 30 ppm) or normal (v: 150 ppm). Figure 2 shows the results obtained by determining the relative amount of mouse fibroblastic cells L929, after their culture in nutrient fluid media with a deuterium content between 30 and 5000 ppm (a: 30 ppm; b: 150 ppm, C: 300 ppm, d: 600 ppm, e: 1250 ppm, f: 5000 ppm). DETAILED DESCRIPTION OF THE INVENTION When the hydrogen obtained by the electrolysis of water is burnt to form water, according to example 1, water containing deuterium is produced in an amount comprised between 30 and 40 ppm. To prepare water with deuterium at higher concentrations, D20 at 99.98% by mass is added to normal water. The culture media suitable for maintaining different families of animal cells in vitro were produced from the waters prepared as just indicated, with different contents of deuterium, dissolving 10 g of an industrially produced dehydrated mixture of amino acids, vitamins, salts and bases [Dulbecco's modified Eagle's medium (D'MEM), code number: 074-01600; Sigma, St. Louis, USA.] In 1 liter of water. 110 ml of bovine serum was added to the solutions thus prepared. The liquid medium thus obtained contained all the compounds necessary to maintain the cells. The growth of L929 mouse fibroblast cells was first studied under in vitro conditions in nutrient media containing deuterium in different amounts (30 to 5000 ppm). With these experiments the division of approximately 400 individual cells was followed. The experiments proved that the growth rate of the cells in a medium prepared with water with deuterium decreased, was reduced from 15 to 20%. Next, it was investigated whether the deuterium concentration of the nutrient media influenced the time necessary for the cells to enter the S phase from the - - called phase Gl after synchronization (figure 1). In Figure 1 it can be seen that, after synchronization, the cell growth started 6 to 8 hours later and that the growth rate was lower in the nutrient media prepared using water with deuterium decreased (v: 30 ppm) than in the preparations using water with a normal amount of deuterium (v: 150 ppm). A method generally accepted in recent years to determine the number of cells, is performed by incubating the cells together with 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl) -5- [(phenylamino) carbonyl hydroxide] -2H-tetrazolium (XTT), compound that is reduced by the cells. The reduced form of this compound shows its maximum absorption at 450 nm and therefore its quantity can be measured photographically. Thus, the corresponding number of cells can be calculated from the optical density (OD) values [Cancer Research 4B, 4827 to 4833 (1988)]. With this method, the effects of lower (v: 30 ppm) and higher (v: 300 to 5000) concentrations of deuterium than natural concentrations on cell proliferation were also studied (figure 2). It was proved with the experiments that the growth rate decreased in the nutrient media prepared with water with deuterium decreased. According to these experiments, deuterium concentrations between 2 and 4 times higher than natural concentrations (300 to 600 ppm) exert an effect - - stimulating the proliferation of cells. [A greater increase in deuterium concentration (1250 to 5000 ppm) makes the inhibition derived from the isotope effect dominant]. Repeated trials with four different families of cells yielded similar results. In the first in vivo experiment, it was investigated how tumor growth was influenced by decreasing the deuterium content in the drinking water of mice. The human breast tumors MDA-MB-231 and MCF-7 were transplanted into two groups of 14 CBA-Ca mice each. The animals of the control group consumed normal water, while from the day of transplantation, the animals of the treated group drank water with deuterium prepared according to the invention. The results are summarized in table 1.

- Table 1 Effect of water with deuterium decreased on breast tumor growth in mice.

Family cells MDA-MB-231 MCF-7 Days Control Treaty Control Treaty 5/5 9/9 6/6 8/8 50 5/5 5/9 6/6 5/8 65 1/1 4/9 2/2 4/7 71 0/0 3/8 1/2 2 / 7 80 0/0 2/7 0/1 0/5 87 0/0 1/6 0/1 0/5 The numbers of the control and treaty groups correspond to the numbers: animals with tumor / animals in total. The results in Table 1 show that there was only a spontaneous regression of the tumor in one animal of the 11 with cancer of the control groups (5 + 6), the others died in the 71st day and in the 80th day respectively after the transplant. In contrast, in the two treated groups, the tumor increased, regressed and then disappeared in 10 animals (59%) of the total of 17 animals with tumor (9 + 8), and one of the animals with tumor, which was not shown in Table 1, the last animal that died from the control group survived 30 days. These animals drank water with 30 ppm of deuterium for 3 weeks and then water with 110 to 120 ppm of deuterium until the end of the experiment. To perform another experiment, prostatic human PC-3 cells were transplanted to mice of type 44 CBA / Ca. Treatment started on the 32nd day after the transplant giving the animals drinking water containing 94 + 5 ppm deuterium. At that time, the mean diameter of the tumor was 10.4 mm in the control group and 10.2 mm in the treated group. (Taking into consideration the body / tumor mass ratio, the treatment of the mice in this phase of the experiment corresponds to starting the cure of a 70 kg weight human being with a 3.5 kg tumor). That is, the treatment started at a very advanced stage of the tumor and this is the reason why the treatment was not as effective as in the first experiment. The numbers in Table 2 represent the numbers: animals with tumor / animals in total, and the average size of the tumor during the course of treatment.

Table 2 Effect of water with decreased deuterium on prostate tumor PC-3 in mice Days Animals with tumor / Mean diameter of animals in total tumor in mm Control Treatments Control Treatments 32 22/22 22/22 10.4 10.2 39 17/17 19/20 14.6 11.1 46 13/13 17/19 22.4 17.5 53 9/9 11/14 21.7 15 , 0 60 6/7 10/13 23.8 15,0 67 3/4 10/13 16.7 18.0 74 3/4 7/10 24.0 18.1 81 3/4 5/8 28, 6 18.0 88 2/3 5/8 37.0 16.6 The results of table 2 show that in the control group and on the 87th day after the transplantation of the tumor cells, only 3 animals survived (13%) of the total of 22, while in the treated group they still lived 8 animals (36%) of the 22, the 88th day. At that time, 2 animals (9%) and 5 animals (23%) of the control and treated groups remained alive. In 3 animals of the treated group a regression of the tumor could be observed. In addition, the data of the mean diameter of the tumor confirm a significant difference between the animals of the control group and the treated group. Based on the data in Table 2, cumulative mortality data are summarized in Table 3.

- Table 3 Cumulative data of mortality due to prostate tumor PC-3 Days > Control Treaties 32 0 0 39 5 2 46 9 3 53 13 8 60 15 9 67 18 9 74 18 12 81 18 14 88 19 14 The results in Table 3 show that the number of animals that perished from the treated group was lower than that of the control group in all phases of the trial. It is worth emphasizing that on the 67th day after the transplant, only 9 animals of the treated group had died, while in the control group the double had perished (18). The importance of this difference is underlined by the fact that the period of tumor development of one week in mice corresponds to a period of 200 to 300 days in humans. Therefore, the data in Table 3 show that the survival period in humans can increase in years, even when the medical cure begins in an advanced state of the disease. In a third experiment, HT-29 colon tumor cells were transplanted into mice. The treatment started on the 24th day after the transplant, giving the animals drinking water with a deuterium content of 94 + 5 ppm. The mean volumes of the tumors can be seen in Table 4. The control group consisted of 13 animals and the group treated in 16 animals. From Table 4 it can be deduced that during the 90-day treatment period the mean volumes of the tumors were considerably lower in the treated group than in the control group.

- Table 4 Effect of water with decreased deuterium on human HT-29 colon tumor cells in mice 'Average volume of the tumor in cm Days Control Treaty 0.16 0.16 20 0.81 0.45 35 2.28 1.88 55 5.82 4.85 70 8.09 6.80 85 19.48 10.96 90 20.74 12.35 Summarizing the results of the animal tests, it can be established that by applying pharmaceutical products according to the invention to cure tumor diseases, a restoration rate of about 50% in the initial phase of the disease can be achieved and the delivery of survival of 20 to 30% in the advanced stage of the disease. These results can be further improved by applying water with an even lower deuterium content. The products of the invention can be applied with - therapeutic purposes in forms containing the active ingredient together with carriers that are inert and physiologically acceptable and / or with auxiliary substances. The active ingredient can be transformed into compositions for oral administration (e.g., solutions, emulsions, suspensions, etc.), parental administration (e.g. injectable solutions) or rectal administration. The active ingredient can also be applied externally, for example in the form of ointments. The pharmaceutical products according to the invention can be prepared following known methods conventionally used in the pharmaceutical industry, that is, by mixing the active agent and the inert organic or inorganic carriers and * processing the mixture in the form of a medicament. As the liquid carrier, preferably water or ethanol can be used. The pharmaceutical products may also contain auxiliary substances conventionally used in the pharmaceutical industry, for example wetting agents, sweeteners, flavorings, buffers, etc. The medicinal solutions according to the invention can be prepared by applying the methods already known and generally used in the food industry to prepare fruit juices, syrups, soft drinks and beers, is - - say adding the active agent to the basic substances of the non-alcoholic beverage industry and beers, such as fruit juices, juice concentrates, flavoring agents, sweeteners, flavoring agents, essential oils, as well as other additives and auxiliary substances used in a manner conventional in the soft drinks and beers industry. The daily dose of the pharmaceutical products of the invention can vary in very broad fields, depending on various factors, for example the activity of the active ingredient, the condition and age of the patient, the type of tumor, the degree of malignancy, etc. In the case of a patient weighing 70 kg, the daily oral dose is 1 to 2 liters of fluid with deuterium decreased, with a deuterium concentration between 0.1 and 110 ppm. The deuterium-depleted water may contain, for example, 30 to 50 g of carbohydrates and other flavoring or flavoring agents, in order to make the pharmaceutical products taste better. In the case of injectable solutions, the daily dose may be from 2 to 6 liters and the concentration of deuterium in the water may vary within wide limits (from 0.1 to 110 ppm). In general, the concentration of deuterium in the water of the patient's body must be decreased daily by at least 0.5 ppm, in order to ensure the desired therapeutic effect. These doses are only informative and the dose to be applied should always be the one prescribed by the doctor. The main advantages of the product and the method of the invention are the following: a) > The procedure provides the opportunity to intervene directly in the regulatory mechanism of cell proliferation in a natural way. b) Tumor diseases can be prevented and cured using the pharmaceutical products of the invention. c) The components of the product do not have secondary toxic effects. d) No harmful waste to the environment occurs in the manufacturing process. e) The manufacturing process can be carried out in a simple way from the technological point of view. f) As the active ingredient is not mutagenic, in the course of the therapeutic treatment, mutant cells are not generated. (Most cytostatic substances applied to date have a strong mutagenic character and often induce the formation of new tumors). g) The application of the pharmaceutical products of the invention produces recovery and does not delay only the development of the disease. The product and preparation process according to the invention are illustrated in more detail in the following examples, which do not limit the claimed field. Eje plp l Production by electrolysis of water with deuterium decreased: S? it undergoes an aqueous solution of KOH of 15 to 20% weight / volume by electrolysis, by direct current at a potential of 2 to 5 V, with a cathode and an anode separated from each other. The hydrogen deposited at the cathode and containing deuterium in a decreasing concentration is burned, and the vapor formed is condensed and collected separately. The water thus obtained has a deuterium content comprised between 30 and 40 ppm which is decreased to 6 to 20 ppm by another new electrolysis. He . The product thus obtained can be used to ensure the fluid demand of patients suffering from tumoral diseases and, as a starting substance, to produce compounds with decreased deuterium content. The final product of the process is distilled water, so it is preferable to add essential salts before using it for human consumption. The final product can be advantageously supplemented with a mixture of salts containing 1000 mg of sodium, 200 mg of potassium, 160 mg of calcium, 88 mg of magnesium, 650 mg of phosphorus and 600 mg of chlorine, calculated for 1 liter.

Example 2 Water production with deuterium decreased by distillation: The water is distilled in a fractionation column of 30 to 50 plates, at a pressure of 30 to 50 millibar and at a temperature comprised between 45 and 50 ° C. The reflux value is maintained between 12 and 13 during the course of the distillation.

To maintain the deuterium concentration at a low level, a ten-fold dilution is applied to the bottom of the column during distillation. Using these parameters, the deuterium concentration of the product at the top of the column is 20 to 30 ppm. The deuterium content of the water can be lowered to a figure between 1 and 10 ppm by increasing the number of plates and / or repeating the distillation process. The final product of the process is distilled water, so it is convenient to add essential salts before using it for human consumption.

EXAMPLE Production of physiological saline solution with decreased deuterium: 8.5 g of NaCl were added to 1 liter of distilled water prepared according to example 1 or 2. The physiological saline solution is normally applied as an infusion after carrying out the usual sterilization process. Applying this form of product, the daily dose can be increased up to 2 to 6 liters in severe cases. Example 4 Production of fruit juices with decreased deuterium: Distilled water prepared according to example 1 or 2 is mixed with a deuterium content of 20 to 30 ppm, with water and concentrated fruit juice as follows: a) 0.8 parts per volume of water with 20 to 30 ppm deuterium + 0.2 part per volume of concentrated fruit juice (the final concentration of deuterium is 45 to 50 ppm), • b) 0.5 parts by volume of water with 20 at 30 ppm deuterium + 0.3 parts per volume of concentrated fruit juice + 0.3 parts by volume of normal water (the final concentration of deuterium is from 85 to 90 ppm) c) 0.3 parts by volume of water with 20 to 30 ppm deuterium + 0.2 parts per volume of juice of concentrated fruit + 0.5 parts per volume of normal water (the final concentration - deuterium is 105 to 110 ppm). Starting with water containing deuterium in a lower concentration, fruit juices with lower concentration of deuterium than indicated above can be prepared. Example 5 Production of non-alcoholic drinks with carbonic acid content: Distilled water prepared according to example 1 or 2, with a deuterium content of 20 to 30 ppm, is mixed with a concentrated alcohol-free beverage containing 50 g / 1 of alcohol. sugar, 5% by volume of orange juice, 6 g / 1 of carbonic acid, 1 g / 1 of citric acid, 500 mg / 1 of ascorbic acid and 500 mg / 1 of natural flavoring agents, as follows: a) 0 , 8 parts by volume of water with 20 to 30 ppm of deuterium + 0.2 parts by volume of a concentrated non-alcoholic beverage (the final concentration of deuterium is 45 to 50 ppm); b) 0.5 parts by volume of water with 20 to 30 ppm of deuterium + 0.3 parts by volume of normal water + 0.2 parts by volume of a concentrated non-alcoholic beverage (the final concentration of deuterium is 85 to 90 ppm); c) 0.3 parts by volume of water with 20 to 30 ppm of deuterium + 0.5 parts by volume of normal water + 0.2 parts by volume of a concentrated non-alcoholic beverage (the final concentration of deuterium is 105 to 110 ppm).

Starting with water containing deuterium in a lower concentration, non-alcoholic beverages with a lower concentration of deuterium than indicated above can be prepared. Example 6 Production of beer with decreased deuterium content: First, soak barley in water with a deuterium content between 0.1 and 110 ppm, to produce the malt, then the barley germinates at a temperature from 5 to 15 ° C in a layer of 5 to 15 cm thick and with good aeration conditions. The germinated barley is dehydrated at a temperature between 56 and 75 ° C, separated from the rootlets of the germination and milled. The milled barley is mixed with an adequate amount of water, with a deuterium content of 0.1 to 110 ppm. The mixture is heated to a temperature of 50 to 75 ° C, filtered and made with hops. The beer with hops is filtered, cooled and inoculated with Saccharomyces cerevisiae. The period of the first fermentation process at 5 or 6 ° C lasts from 10 to 14 days. The secondary fermentation period is carried out in closed tanks, at 0 ° C and for a few weeks. Next, the fabricated beer is filtered, bottled and pasteurized.

The deuterium content of the beer prepared according to this example depends on the deuterium content of the water used, which also influences the deuterium content of the ethanol and the other components. • E-example 7 Production of a moisturizing ointment with decreased deuterium content: The moisturizing ointment is manufactured in a conventional manner using water with decreased deuterium. The composition of a hydrating ointment commonly used for 1000 g of product, is as follows: Unguentum hydrosum 550 g Unguentum stearini 150 g Distillate water, with 30 to 40 ppm deuterium 300g

Claims (4)

1. NOVELTY OF THE INVENTION Having described the present invention is considered as a novelty and therefore claimed as property described in the following claims: 1. Process for the preparation of products to cure tumoral diseases comprising water with a deuterium content between 0.1 and 110 ppm and / or aqueous solutions, suitable for human consumption, characterized in that it comprises the operations of producing by electrolysis and / or distillation water and / or an aqueous solution with a deuterium content comprised between 0.1 and 110 ppm as active agent , and transforming the water and / or the aqueous solution thus produced with a deuterium content comprised between 0.1 and 110 ppm, optionally together with carriers and auxiliary substances, into pharmaceutical products or medicinal solutions.
2. 2. Process according to claim 1, characterized in that the physiological saline solutions are prepared as pharmaceutical products with a deuterium content between 0.1 and 110 ppm.
3. 3. Method according to claim 1, characterized in that fruit syrups, non-alcoholic beverages and beer without alcohol or reduced alcohol content are prepared as medicinal solutions with a deuterium content between 0.1 and 1 ppm .
4. 4. Method according to claim 1, characterized in that the product is formulated in the form of an injectable solution, infusion solution, syrup, juice or moisturizing ointment, with a deuterium content comprised between 0.1 and 110 ppm.